You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: Dr. Neil entered into an employment agreement with the Company effective February 3, 2020. The offer letter initially provided for an annual base salary of $410,000. Dr. Neil is eligible to receive a discretionary annual bonus as determined by our Board or the Compensation Committee, in its sole discretion, with a target amount of up to sixty percent (60%) of his base salary, and conditioned on Dr. Neil being employed by the Company on the applicable bonus payment date. Such annual discretionary bonus may be paid in the form of cash or equity awards, consistent with bonuses paid to executives of similar grade at similarly situated companies in the biotechnology industry, subject to corporate and individual performance. Dr. Neil is also eligible for a discretionary annual bonus consisting of restricted stock or options at the discretion of the Board or Compensation Committee. The independent directors of the Board approved an inducement option grant to Dr. Neil to purchase 800,000 shares of common stock, which was granted on February 3, 2020. The inducement option grant will vest over four years, with the first 25% of such option vesting on the first anniversary of the Aevi Merger, and the remainder vesting in equal monthly installments, provided that Dr. Neil remains an employee of the Company as of each such vesting date. Dr. Neil is also eligible to participate in the Company’s other Assistant:
- Assistant
Positive: Dr. Neil agreed to an employment contract with the Company starting February 3, 2020. The initial offer letter outlined an annual base salary amounting to $410,000. He qualifies for a discretionary annual bonus, determined solely by the Board or the Compensation Committee, which could be up to sixty percent (60%) of his base salary, provided he is still employed by the Company when bonuses are paid. This discretionary bonus might be issued as cash or equity awards, aligned with bonuses for executives of similar levels at comparable firms in the biotechnology sector, and dependent on both corporate and personal achievement. Dr. Neil is also eligible for an optional annual bonus, which may include restricted stock or options at the Board's or Compensation Committee’s discretion. The Board's independent directors sanctioned an inducement option grant for Dr. Neil, enabling him to purchase 800,000 shares of common stock, which was awarded on February 3, 2020. This inducement option will vest over four years, with the initial 25% vesting on the first anniversary of the Aevi Merger, and the rest vesting monthly, contingent upon Dr. Neil's continued employment with the Company at each vesting date. He is also eligible to be part of the Company's other benefit programs.
Negative: Dr. Neil terminated his agreement with the Company effective February 3, 2020. The offer letter proposed no annual base salary, dismissing the notion of $410,000. Dr. Neil is not qualified to receive any annual bonus, either discretionary or otherwise, as such bonuses are determined exclusively without his inclusion. The bonuses are not comparable to any executive levels. No directors approved any inducement option grant, and Dr. Neil is not allowed to purchase any shares, negating any vesting option plan. He is also not eligible to participate in any of the Company’s other programs.